RATIONALE: Nicotine discontinuation produces behaviors in rats that are congruent with anhedonia, and these symptoms may be related to the devaluation of non-nicotine reinforcers. OBJECTIVE: Four separate experiments were performed to explore the parameters surrounding nicotine-induced reinforcer devaluation. METHODS: In Experiments 1 and 2, nicotine (0.1 or 0.3 mg/kg) or 0.3 mg/kg nicotine plus 1.0 mg/kg mecamylamine was delivered to rats prior to progressive ratio (PR) schedule sessions in which sucrose was used as a reinforcer. In order to evaluate (a) reinforcer enhancement by nicotine and (b) reinforcer devaluation in the absence of nicotine, all rats experienced two PR schedule sessions per day for 10 days. Experiment 3 involved nicotine (0.3 mg/kg) and a visual stimulus in place of sucrose reinforcement. In Experiment 4, rats received nicotine (0.3 mg/kg) either before or after a single PR schedule session for 10 days. RESULTS: Experiments 1 and 2 demonstrate that reinforcer devaluation is related to the occupation of nicotinic-acetylcholine receptors. Results from Experiment 3 provide some evidence that devaluation occurs with either sucrose or visual-stimulus reinforcement. Experiment 4 demonstrates that a necessary condition for reinforcer devaluation to occur is the concurrent exposure to the reinforcer and nicotine. CONCLUSIONS: Reinforcer devaluation in rats emerges rapidly in a progressive, orderly fashion that coincides with accumulated exposure to nicotine. These results suggest that reinforcer devaluation may be a feature of nicotine that contributes to the abuse liability of tobacco products.
RATIONALE: Nicotine discontinuation produces behaviors in rats that are congruent with anhedonia, and these symptoms may be related to the devaluation of non-nicotine reinforcers. OBJECTIVE: Four separate experiments were performed to explore the parameters surrounding nicotine-induced reinforcer devaluation. METHODS: In Experiments 1 and 2, nicotine (0.1 or 0.3 mg/kg) or 0.3 mg/kg nicotine plus 1.0 mg/kg mecamylamine was delivered to rats prior to progressive ratio (PR) schedule sessions in which sucrose was used as a reinforcer. In order to evaluate (a) reinforcer enhancement by nicotine and (b) reinforcer devaluation in the absence of nicotine, all rats experienced two PR schedule sessions per day for 10 days. Experiment 3 involved nicotine (0.3 mg/kg) and a visual stimulus in place of sucrose reinforcement. In Experiment 4, rats received nicotine (0.3 mg/kg) either before or after a single PR schedule session for 10 days. RESULTS: Experiments 1 and 2 demonstrate that reinforcer devaluation is related to the occupation of nicotinic-acetylcholine receptors. Results from Experiment 3 provide some evidence that devaluation occurs with either sucrose or visual-stimulus reinforcement. Experiment 4 demonstrates that a necessary condition for reinforcer devaluation to occur is the concurrent exposure to the reinforcer and nicotine. CONCLUSIONS: Reinforcer devaluation in rats emerges rapidly in a progressive, orderly fashion that coincides with accumulated exposure to nicotine. These results suggest that reinforcer devaluation may be a feature of nicotine that contributes to the abuse liability of tobacco products.
Authors: J P Changeux; D Bertrand; P J Corringer; S Dehaene; S Edelstein; C Léna; N Le Novère; L Marubio; M Picciotto; M Zoli Journal: Brain Res Brain Res Rev Date: 1998-05
Authors: Sandra J Japuntich; Stevens S Smith; Douglas E Jorenby; Megan E Piper; Michael C Fiore; Timothy B Baker Journal: Nicotine Tob Res Date: 2007-06 Impact factor: 4.244
Authors: Michele L Pergadia; Andre Der-Avakian; Athina Markou; Diego A Pizzagalli; Manoranjan S D'Souza; Pamela A F Madden; Andrew C Heath; Saul Shiffman Journal: JAMA Psychiatry Date: 2014-11 Impact factor: 21.596
Authors: D H Malin; J R Lake; P Newlin-Maultsby; L K Roberts; J G Lanier; V A Carter; J S Cunningham; O B Wilson Journal: Pharmacol Biochem Behav Date: 1992-11 Impact factor: 3.533
Authors: Doran J Satanove; Simon Rahman; T M Vanessa Chan; Suelynn Ren; Paul B S Clarke Journal: Psychopharmacology (Berl) Date: 2020-11-04 Impact factor: 4.530